Five years ago, in early 2020, we all became aware of a new pandemic, COVID-19.

It quickly became apparent that in some patients the virus was associated with a severe coagulopathy, resulting in significant morbidity and mortality.

Emerging evidence has indicated that coagulation changes play a major role in the pathophysiology of COVID, particularly Long-COVID, the persistent symptoms following infection.

In this presentation, Dr. Resia Pretorius discusses use of cutting edge laboratory studies in coagulation and vascular biology, as it applies to COVID.